Cel-Sci/$CVM
1D1W1MYTD1Y5YMAX
About Cel-Sci
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
- Ticker
- $CVM
- Sector
- Health
- Primary listing
- AMEX
- Employees
- 44
- Headquarters
- Vienna, United States
- Website
- cel-sci.com
Cel-Sci Metrics
BasicAdvanced
$27M
-
-$2.57
0.56
-
Price and volume
Market cap
$27M
Beta
0.56
52-week high
$12.68
52-week low
$0.89
Average daily volume
203K
Financial strength
Current ratio
1.477
Quick ratio
1.287
Long term debt to equity
47.417
Total debt to equity
72.098
Interest coverage (TTM)
-50.19%
Profitability
EBITDA (TTM)
-20.257
Management effectiveness
Return on assets (TTM)
-66.82%
Return on equity (TTM)
-252.53%
Valuation
Price to book
2.5
Price to tangible book (TTM)
2.52
Price to free cash flow (TTM)
-0.823
Free cash flow yield (TTM)
-121.50%
Free cash flow per share (TTM)
-1.895
Growth
Earnings per share change (TTM)
-71.71%
3-year earnings per share growth (CAGR)
-52.03%
10-year earnings per share growth (CAGR)
-32.72%
Cel-Sci News
AllArticlesVideos
Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients
Business Wire1 month ago
CEL-SCI Corporation Announces Pricing of Offering
Business Wire3 months ago
CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabia
Business Wire3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.